Prognostic Value of Lymph Node and Spleen Activity in [18F]FDG PET-CT in Lung Adenocarcinoma and Squamous Cell Carcinoma

Yıl 2019, Cilt: 46 Sayı: 1, 1 - 10, 03.03.2019

Halil Komek Nadiye Akdeniz , Zuhat Urakci Canan Can Serdar Altindag

https://doi.org/10.5798/dicletip.534806

Öz

Objective: We aimed to investigate the prognostic value of primary mass, spleen and lymph node metabolic activity in [18F]FDG PET-CT as well as the prognostic value of neutrophil lymphocyte ratio (NLR) and platelet lymphocyte ratio (TLR) in patients with lung adenocarcinoma and squamous cell carcinoma.

Objective: We aimed to investigate the prognostic value of primary mass, spleen and lymph node metabolic activity in [18F]FDG PET-CT as well as the prognostic value of neutrophil lymphocyte ratio (NLR) and platelet lymphocyte ratio (TLR) in patients with lung adenocarcinoma and squamous cell carcinoma.

Results:  The  SUVmax  spleen/liver  and  SUVmax  lymph  node/liver  ratios  were  significantly  higher  in  the  exitus subgroup  of  squamous  cell  carcinoma  (p=0.025,  p=0.043;  respectively).  The  SUVmax  lymph  node/liver  ratio  was found to be a  predictor for  survival in squamous cell carcinoma (p=0.019, OR:1.282). The SUVmax spleen/liver and SUVmax lymph node/liver ratios were similar between subgroups of adenocancer. 
Conclusions:  The  SUV  ratios  of  the  spleen  were  not  a  predictor  for  survival  in  both  groups.  The  SUVmax  lymph node/liver ratio was found to be a predictor for survival in squamous cell carcinoma. However, NLR and PLR were not found to be prognostic factors. 

Anahtar Kelimeler

Lung cancer, spleen activity, survival, [18F, FDG PET-CT

Kaynakça

• 1. Vansteenkiste J, Fischer BM, Dooms C, et all. Positron emission tomography in prognostic and therapeutic assessment of lung cancer: systematic review. Lancet Oncol. 2004; 5: 531-40.
• 2. de Geus-Oei LF, van Krieken JH, Aliredjo RP et all. Biological correlates of FDG uptake in non-small cell lung cancer. Lung Cancer. 2007; 55: 79-87.
• 3. chuurbiers OC, Meijer TW, Kaanders JH, et all. Glucose metabolism in NSCLC is histology-specific and diverges the prognostic potential of 18FDG-PET for adenocarcinoma and squamous cell carcinoma.. J Thorac Oncol. 2014; 9: 1485-93.
• 4. Lee HY, Lee HJ, Kim YT, et all. Value of combined interpretation of computed tomography response and positron emission tomography response for prediction of prognosis after neoadjuvant chemotherapy in non- small cell lung cancer. J Thorac Oncol. 2010; 5: 497- 503.
• 5. Nair VS, Krupitskaya Y, Gould MK. Positron emission tomography 18F fluorodeoxyglucose uptake and prognosis in patients with surgically treated, stage I non small cell lung cancer: a systematic review. J Thorac Oncol. 2009;12: 1473-9.
• 6. Lee JW, Na JO, Kang DY, Lee SY, Lee SM. Prognostic Significance of FDG Uptake of Bone Marrow on PET/CT in Patients With Non-Small-Cell Lung Cancer After Curative Surgical Resection. Clin Lung Cancer. 2017; 18: 198-206.
• 7. Prévost S, Boucher L, Larivée P, et all. Bone marrow hypermetabolism on 18F-FDG PET as a survival prognostic factor in non small cell lung cancer. 2006; 4:559-65.
• 8. Blebea JS, Houseni M, Torigian DA, et all. Structural and functional imaging of normal bone marrow and evaluation of its age-related changes. Semin Nucl Med. 2007; 37:185-94.
• 9. Wang J, Jia Y, Wang N, et all. The clinical significance of tumor-infiltrating neutrophils and neutrophil-to- CD8+ lymphocyte ratio in patients with resectable esophageal squamous cell carcinoma. J Transl Med. 2014; 12:7.
• 10. Xue P, Kanai M, Mori Y, et al. Neutrophil-to- lymphocyte ratio for predicting palliative chemotherapy outcomes in advanced pancreatic cancer patients. Cancer Med. 2014; 3: 406-415.
• 11. de Geus-Oei LF, van der Heijden H, Corstens F, et all. Predictive and prognostic value of FDG-PET in nonsmall-cell lung cancer. Cancer. 2007; 110: 1654-64.
• 12. Al-Jahdali H, Khan AN, Loutfi S, et all. Guidelines for the role of FDG-PET/CT in lung cancer management. J Infect Public Health. 2012; 5: 35-40.
• 13. Liu NB, Zhu L, Li MH, et all. Diagnostic value of 18F-FDG PET/CT in comparison to bone scintigraphy, CT and 18F-FDG PET for the detection of bone metastasis. Asian Pac J Cancer Prev. 2013; 14: 3647-52.
• 14. Mutlu H, Buyukcelik A, Erden A, et all. Staging with PET-CT in patients with locally advanced nonsmall cell lung cancer is superior to conventional staging methods in terms of survival. Asian Pac J Cancer Prev. 2013; 14: 3743-6.
• 15. Motono N, Ueno M, Tanaka M, et all. Differences in the prognostic significance of The SUVmax between patients with resected pulmonary Adenocarcinoma and squamous cell carcinoma. Asian Pac J Cancer Prev. 2014; 15: 10171-4.
• 16. Vansteekiste JF, Stroobants SG, Dupont PJ, et all. Prognostic importance of the standardized uptake value on 18F-fluoro-2-deoxy-glucose-positron emission tomography scan in non-small-cell lung cancer. An analysis of 125 cases. J Clin Oncol. 1999; 17: 3201-6.
• 17. Patz EF Jr, Connolly J, Herndon J. Prognostic value of thoracic FDG PET imaging after treatment for non-small cell lung cancer. AJR. 2000; 174: 769-74.
• 18. Higashi K, Ueda Y, Arisaka Y, et all. 18F-FDG uptake as a biologic prognostic factor for recurrence in patients with surgically resected non-small cell lung cancer. J Nucl Med. 2002; 43: 39-45.
• 19. Jin F, Zhu H, Fu Z, Kong L, Yu J. Prognostic value of the standardized uptake value maximum change calculated by dual-time-point (18)F-fluorodeoxyglucose positron emission tomography imaging in patients with advanced non-small-cell lung cancer. Onco Targets Ther. 2016; 19: 2993-9.
• 20. Park JK, Kim JJ, Moon SW. Variations in positron emission tomography-computed tomography findings for patients receiving neo adjuvant and non-neo adjuvant therapy for non-small cell lung cancer. J Thorac Dis. 2017; 2: 344-54.
• 21. Kraal G. Cells in the marginal zone of the spleen. Int Rev Cytol. 1992; 132: 31-74.
• 22. Nam HY, Kim SJ, Kim IJ, et all. The clinical implication and prediction of diffuse splenic FDG uptake during cancer surveillance. Clin Nucl Med. 2010; 35: 759-63.
• 23. Pak K, Kim SJ, Kim IJ, et all. Impact of cytokines on diffuse splenic 18F-fluorodeoxyglucose uptake during positron emission tomography/computed tomography. Nucl Med Commun. 2013; 34: 64-70.
• 24. Salaun PY, Gastinne T, Bodet-Milin C, et all. Analysis of 18F-FDG PET diffuse bone marrow uptake and splenic uptake in staging of Hodgkin’s lymphoma: a reflection of disease infiltration or just inflammation? Eur J Nucl Med Mol Imaging. 2009; 36: 1813-21.
• 25. Bural GG, Torigian DA, Chen W, et all. Increased 18F-FDG uptake within the reticuloendothelial system in patients with active lung cancer on PET imaging may indicate activation of the systemic immune response. Hell J Nucl Med. 2010; 13: 23-5.
• 26. Aktaş GE, Sarıkaya A, Demir SS. Diffusely Increased Splenic Fluorodeoxyglucose Uptake in Lung Cancer Patients. Turk Thorac J. 2017; 18: 6-10.
• 27. Komek H, Altindag S and Can C. Association of PET Scan Parameters of Pulmonary Masses and Reticuloendothelial System with Hematologic Parameters. J Nucl Med Radiat Ther. 2017; 8: 2.
• 28. Nikolić I, Kukulj S, Samaržija M et all. Neutrophil-to-lymphocyte and platelet-to-lymphocyte ratio help identify patients with lung cancer, but do not differentiate between lung cancer subtypes. Croat Med J. 2016; 3: 287-92.
• 29. Gun XB, Tian T, Tian XJ et all. Prognostic significance of neutrophil-to-lymphocyte ratio in non-small cell lung cancer: ameta-analysis. Sci Rep. 2015; 5: 12493.
• 30. Zhang H, Zhang L, Zhu K et all. Prognostic significance of combination of preoperative platelet count and neutrophil-lymphocyte ratio (COP-NLR) in patients with non-small cell lung cancer: based on a large cohort study. PLoS ONE. 2015; 10: e0126496.
• 31. Unal D, Eroglu C, Kurtul N, et all. Are neutrophil/lymphocyte and platelet/lymphocyte rates in patients with non-small cell lung cancer associated with treatment response and prognosis? Asian Pac J Cancer Prev. 2013; 14: 5237-42.